Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

27.60
-0.4150-1.48%
Volume:4.46M
Turnover:123.98M
Market Cap:156.93B
PE:36.32
High:28.00
Open:27.90
Low:27.59
Close:28.00
52wk High:29.21
52wk Low:23.62
Shares:5.69B
Float Shares:5.64B
Volume Ratio:0.96
T/O Rate:0.08%
Dividend:1.72
Dividend Rate:6.23%
EPS(TTM):0.7599
EPS(LYR):1.36
ROE:5.01%
ROA:5.78%
PB:1.84
PE(LYR):20.23

Loading ...

Pfizer Stock Eyes New Boom With Obesity And Alopecia Bets

TIPRANKS
·
Sep 12

AstraZeneca's Breast Cancer Pill Fails in Late-Stage Trial

Reuters
·
Sep 12

For Novartis, M&A is Both a Disease and Cure

Reuters
·
Sep 11

Pfizer Advances Alopecia Areata Drug Ritlecitinib in Key Phase 3 Trial

TIPRANKS
·
Sep 11

Novartis India Hits Record High After Recent Acquisition, Distribution Deal

Reuters
·
Sep 10

TwoStep Therapeutics Raises $62.5 Million in Series a Led by Insight Partners, Medical Excellence Capital

Reuters
·
Sep 10

BMO Capital Adjusts Price Target on Pfizer to $35 From $30, Keeps Outperform Rating

MT Newswires Live
·
Sep 09

NYSE Most Active Issues

Dow Jones
·
Sep 09

Pfizer Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 09

Pfizer CEO Bourla to Speak at Morgan Stanley Global Healthcare Conference Webcast

Reuters
·
Sep 08

The Second Act of Biotech

TIPRANKS
·
Sep 07

Novartis India to Acquire 'Minipress' Trademarks from Pfizer

Reuters
·
Sep 07

Pfizer Ramps Up Obesity And Eczema Bets, Investors Watch

TIPRANKS
·
Sep 05

Pfizer Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 05

Pfizer’s Next Move in Obesity Drugs: What the New VESPER-JM Trial Means for PFE Investors

TIPRANKS
·
Sep 05

Pfizer Steps Up in Obesity Race With New Phase 3 Berobenatide Trial in Japan

TIPRANKS
·
Sep 05

Pfizer’s Tilrekimig Eczema Trial: A Fresh Phase 3 Catalyst for PFE Investors

TIPRANKS
·
Sep 05

Pfizer’s Migraine Tablet Study Wraps Up, Supporting Pipeline Flexibility for PFE Investors

TIPRANKS
·
Sep 05

Pfizer Announces Q3 2026 Dividend of R$ 0.37 Per Unit for Brpfizbdr 006

Reuters
·
Sep 03

Medicus Pharma Shares Down 20.5% Premarket; Co, Pfizer Enter Licensing Deal for Experimental Cancer Therapy

THOMSON REUTERS
·
Sep 03